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cited unanswered questions argue for a cautious 
approach to vaccination policy until trials have been 
completed and fully reported.
George F. Sawaya, M.D. 
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San Francisco, CA 94118
Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of 
a quadrivalent prophylactic human papillomavirus (types 6, 11, 
16, and 18) L1 virus-like-particle vaccine against high-grade vul-
val and vaginal lesions: a combined analysis of three random-
ised clinical trials. Lancet 2007;369:1693-702.
Cancer of the vulva. Bethesda, MD: National Cancer Insti-
tute, 2007. (Accessed August 23, 2007, at http://seer.cancer.gov/
statfacts/html/vulva.html.)
Drs. Agosti and Goldie Reply: As we noted, the 
need for long-term follow-up data are important, 
which Suba and Raab emphasize. Furthermore, it 
is imperative that momentum behind efforts in the 
past decade to develop feasible options for cervical-
cancer screening in low-resource settings contin-
ues to build. The Bill and Melinda Gates Founda-
tion provided $55.6 million to the Alliance for 
Cervical Cancer Prevention to promote screening 
and $13 million toward the development of low-
cost HPV DNA tests and other tests. We believe it 
is inequitable to exclude women in developing 
1.
2.
countries from the potential benefits of vaccina-
tion, new technology, and screening approaches 
that appear to be promising.1
We emphasized that an integrated approach 
that includes screening and vaccination is likely to 
prevent the greatest number of deaths from cervi-
cal cancer. However, countries will make their 
own decisions about the best strategic approach 
to cervical-cancer prevention, accounting for local 
epidemiologic factors and disease burden,2 com-
peting priorities, and the cost-effectiveness, af-
fordability, and feasibility of vaccination programs 
targeting adolescents and the screening of adult 
women. We urge that attention be given to real-
world solutions for preventing death from cervical 
cancer in women living in poverty.
Jan M. Agosti, M.D.
Bill and Melinda Gates Foundation 
Seattle, WA 98102
Sue J. Goldie, M.D., M.P.H.
Harvard School of Public Health 
Boston, MA 02115
Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of vi-
sual screening on cervical cancer incidence and mortality in Tamil 
Nadu, India: a cluster-randomized trial. Lancet 2007;370:398-406.
World Health Organization. WHO/ICO (Institut Català 
d’Oncologia) Information Centre on HPV and cervical cancer. (Ac-
cessed August 23, 2007, at http://www.who.int/hpvcentre.)
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Human Papillomavirus and Oropharyngeal Cancer
To the Editor: The study by D’Souza et al. (May 
10 issue)1 on oropharyngeal squamous-cell carci-
nomas associated with human papillomavirus 
(HPV) provides important epidemiologic insights 
into a cancer that is becoming increasingly com-
mon in the United States.2 However, the molecu-
lar mechanisms of carcinogenesis in HPV-associ-
ated oropharyngeal squamous-cell carcinomas 
remain unclear.
The integration of HPV type 16 (HPV-16) into 
the host genome is an important mechanism in 
cervical carcinogenesis,3 but there is no direct evi-
dence that this process occurs in oropharyngeal 
squamous-cell carcinomas. The authors state that 
Southern blot, real-time polymerase-chain-reaction 
(PCR), and fluorescence in situ hybridization 
analyses4 have established integration sites but 
that these methods provide only indirect evidence. 
Direct evidence would require observation of the 
viral DNA sequence either flanked or attached to 
one end of human DNA (junction sequences). Mel-
lin et al.5 did not observe this finding in HPV-16–
positive tonsillar carcinomas. We previously used 
restriction-site PCR in more than 100 HPV-16 and 
HPV-18 cervical cancers to identify many of these 
junction sequences.6 However, when we used this 
same technique in 40 oropharyngeal squamous-
cell carcinomas that were positive for HPV-16, we 
did not detect junction sequences (unpublished 
data). This finding, which suggests a mechanism 
of carcinogenesis that is distinct from that in cervi-
cal cancer, warrants further investigation.
Odey C. Ukpo, M.S. 
Eric J. Moore, M.D. 
David I. Smith, Ph.D.
Mayo Clinic 
Rochester, MN 55905  
oukpo1979@gmail.com
D’Souza G, Kreimer AR, Viscidi R, et al. Case–control study 
of human papillomavirus and oropharyngeal cancer. N Engl J 
Med 2007;356:1944-56.
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To the Editor: Little is known about the natural 
history of oral HPV infection.1 In a cohort of 360 
healthy students (mean age, 18.7 years), 69% of 
whom were female,2 we tested oral cytobrush sam-
ples for HPV DNA by means of multiplex PCR. Of 
these students, 20 (5.6%) were positive for HPV. 
Three years later, 8 of 183 students who were 
retested (4.4%) were positive, and 1 had persistent 
infection. Oral HPV infection was unusual, and 
the persistence of infection was rare.
Of the 183 students who were retested, 28 were 
sexually inactive, and all these students were HPV-
negative. Of the sexually active students, 100% of 
those who were HPV-positive had had both pene-
trative and oral–genital sex in the previous 3 years; 
of those sexually active students who were HPV-
negative, 88% had had only penetrative sex and 
86% had had only oral–genital sex. These findings 
support the hypothesis that oral HPV is transmit-
ted through sexual contact and that oral–genital 
contact is the likely mechanism.
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To the Editor: D’Souza et al. report a very high 
prevalence of HPV involving 72% of oropharyngeal 
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squamous-cell carcinomas. This finding is unlikely 
to be related to the detection method,1 since in 
situ hybridization was used, a reliable technique 
with a test outcome that is often similar to that 
of viral oncogene transcript analysis.2 We previ-
ously reported that in a Dutch cohort, 6 of 37 
oropharyngeal carcinomas (16%) contained tran-
scriptionally active HPV.3 This prevalence differs 
significantly (P<0.001) from that reported by 
D’Souza et al. A review article also reported a prev-
alence of HPV in oropharyngeal carcinomas that 
was much lower than 72%.4 We wonder whether 
the associations reported by DeSouza et al. can 
be extrapolated to other populations.
Boudewijn J. Braakhuis, Ph.D. 
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C. René Leemans, M.D., Ph.D.
VU University Medical Center 
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96:998-1006.
Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human 
papillomavirus types in head and neck squamous cell carcino-
mas worldwide: a systematic review. Cancer Epidemiol Biomark-
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The author replies: The results of in situ hy-
bridization correlate with viral oncogene expres-
sion in our laboratory (unpublished data). There-
fore, it is unlikely that the high prevalence of HPV 
in oropharyngeal cancers that we found can be ex-
plained by false positive misclassification. How-
ever, our study was performed in a hospital and was 
not population-based. We cannot exclude the pos-
sibility that subjects who did not have traditional 
risk factors were more likely to participate in the 
study. The HPV prevalence of 72% was similar to 
the 63% prevalence in cancers of the oropharynx 
that were collected throughout the United States 
in a clinical trial conducted by the Eastern Coop-
erative Oncology Group.1
We acknowledge that the fraction of oropharyn-
geal cancers caused by HPV in the United States 
may differ from that in other geographic regions. 
Cross-sectional prevalence in a population would 
largely be driven by incidence rates for HPV-posi-
tive and HPV-negative squamous-cell cancers of 
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the head and neck. One might reasonably expect 
that the relative incidence of these two cancers 
would be driven by local societal mores — for ex-
ample, the prevalence of alcohol and tobacco use, 
sexual behaviors, and other cofactors (including 
diet and oral hygiene) in a population. Incidence 
rates may also be quite dynamic, because behav-
iors may change considerably over time. For in-
stance, a significant increase in the prevalence of 
HPV-associated tonsillar cancer from about 23% 
in the 1970s to 68% in the period from 2000 
through 2002 was reported in Sweden.2 Therefore, 
geographic variation in the prevalence of HPV in 
oropharyngeal cancers may be strongly influenced 
by the region and calendar period sampled.
Although viral integration occurs in the major-
ity of cervical cancers, it is neither necessary for 
nor specific to invasive carcinoma.3 Increased ex-
pression and stability of viral oncogene transcripts 
occur as a consequence of viral integration. Analo-
gous deregulation of viral oncogene expression 
may occur in episomal virus through methylation 
or mutation of the viral upstream regulatory re-
gion.3 Although we agree with Ukpo et al. that 
patterns of in situ hybridization and RT-PCR are 
indirect measures of integration, analysis of restric-
tion-fragment–length polymorphisms by Southern 
blot hybridization is a direct measure. Viral inte-
gration into the genome of head-and-neck squa-
mous-cell carcinoma has been demonstrated by 
this method4 and through the cloning of viral-cell 
genome fusion sites,5 albeit in few cases.
Although oral HPV infection is now recognized 
as a causative factor for a subgroup of head-and-
neck squamous-cell carcinomas, little is known 
about the natural history of oral HPV infection. 
Natural-history studies are needed to gain a bet-
ter understanding of the risk factors for acquisi-
tion of oral HPV infection and the factors that af-
fect the duration of infection.
Maura L. Gillison, M.D., Ph.D.
Johns Hopkins Medical Institutions 
Baltimore, MD 21231 
gillima@jhmi.edu
Fakhry C, Westra WH, Li S, et al. Prognostic significance of 
human papillomavirus (HPV) tumor status for patients with 
head and neck squamous cell carcinoma (HNSCC) in a prospec-
tive, multi-center phase II clinical trial. J Clin Oncol 2007; 
Suppl:25. abstract.
Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human 
papillomavirus as a risk factor for the increase in incidence of 
tonsillar cancer. Int J Cancer 2006;119:2620-3.
Pett M, Coleman N. Integration of high-risk human papil-
lomavirus: a key event in cervical carcinogenesis? J Pathol 2007; 
212:356-67.
Steenbergen RD, Hermsen MA, Walboomers JM, et al. Inte-
grated human papillomavirus type 16 and loss of heterozygosity 
at 11q22 and 18q21 in an oral carcinoma and its derivative cell 
line. Cancer Res 1995;55:5465-71.
Ragin CC, Reshmi SC, Gollin SM. Mapping and analysis of 
HPV16 integration sites in a head and neck cancer cell line. Int J 
Cancer 2004;110:701-9.
1.
2.
3.
4.
5.
Bariatric Surgery for Morbid Obesity
To the Editor: In his review of the surgical treat-
ment of morbid obesity, DeMaria (May 24 issue)1 
lists key components of the preoperative medical 
evaluation; these components include screening 
for diabetes, hypertension, coronary artery disease, 
sleep apnea, pulmonary hypertension, and mus-
culoskeletal disease. However, the role of esopha-
gogastroduodenoscopy in this evaluation should 
also be mentioned. Although its routine use re-
mains controversial,2,3 there is evidence for rec-
ommending esophagogastroduodenoscopy with 
biopsy and assessment of samples for Helicobacter 
pylori in all patients planning to undergo bariatric 
surgery, even if they are asymptomatic.4-6 Several 
arguments provide support for this statement. First, 
there is a lack of correlation between symptoms 
and endoscopic findings.4,5 Second, in patients 
who undergo Roux-en-Y gastric bypass, the by-
passed gastric and duodenal mucosa may no lon-
ger be within the reach of the endoscope postop-
eratively, making it more difficult to treat lesions 
that could have been diagnosed preoperatively.5 Fi-
nally, routine esophagogastroduodenoscopy has 
been shown to have a high diagnostic yield and a 
relatively low cost.5
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